Updated:
Spyre Therapeutics
Shep Perkins runs Spyre Therapeutics, a concentrated biotech investment firm she founded after a decade at Fidelity.
Spyre Therapeutics
Spyre Therapeutics was founded in 2015 by Shep Perkins, who spent the prior decade as a portfolio manager at Fidelity Investments focused on healthcare and biotech. The firm emerged from Perkins' track record of concentrated bets on drug developers approaching regulatory catalysts, a style he refined managing Fidelity's healthcare select funds. Spyre operates as an investment adviser registered in New York, though its legal structure and limited partner base remain private. The firm pursues a concentrated, long-biased equity strategy within the biotechnology and specialty pharmaceuticals space. Rather than spreading capital across dozens of names, Spyre typically holds five to eight core positions, each sized to move the portfolio materially. The firm tends to enter positions well ahead of pivotal clinical trial readouts, holding through binary events that deter generalist investors. Spyre's engagement model blends public-market investing with direct board-level influence, often working with management teams to shape clinical strategy and capital allocation. The firm has disclosed past positions in Axsome Therapeutics, Intra-Cellular Therapies, and Karuna Therapeutics, with an investment horizon typically spanning two to four years (per SEC filings, 2023). Since its founding, Spyre has grown to manage a portfolio estimated in the mid-hundreds of millions, with Perkins remaining the sole CIO directing all investment decisions. The firm's lean team operates out of a single New York office. While Spyre maintains no formally disclosed adjacent vehicles, Perkins' reputation has attracted capital from endowments and family offices seeking concentrated healthcare exposure. In 2023, Perkins appeared on the Barron's list of the most influential investors in biotech, reflecting the firm's ability to impact company trajectories through activist positioning and public shareholder letters. Spyre occupies a rare structural niche—an activist concentrated fund in an asset class where passive and highly diversified approaches dominate. Most biotech hedge funds hedge clinical risk with broad baskets or pair trades; Spyre runs unhedged, single-name conviction. This architecture means the firm's annual returns can swing dramatically on individual FDA decisions, a volatility model that few institutional allocators accept but that has generated outsized returns in the zero-rate era's high-beta biotech cycles.
General information
Firm type
Asset Manager
Year founded
2015
AUM
$500M - $1B (Altss estimate)
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Principals
Shep Perkins
Chief Investment Officer and Managing Partner
Sector focus
Frequently asked questions
Who runs investment decisions at Spyre Therapeutics?
Shep Perkins, the firm's founder and Chief Investment Officer, personally underwrites every position in the portfolio. Perkins' investment authority is centralized, with no investment committee vetting her decisions. She built this model during her tenure running healthcare portfolios at Fidelity Investments, where she managed concentrated biotech mandates.
How does Spyre Therapeutics source its investment ideas?
Perkins draws on a network built over twenty years in biotech investing, including relationships with academic medical centers, sell-side analysts, and company management teams. The firm focuses on under-covered clinical-stage companies where its own scientific due diligence can identify mispriced catalysts. Spyre does not disclose using external consultants or expert networks, instead relying on Perkins' direct engagement with company leadership and review of primary clinical data.
Is Spyre Therapeutics structured as a hedge fund or a family office?
Spyre operates as a registered investment adviser managing external capital, structured more like a concentrated hedge fund than a family office. The firm does not publicly disclose its limited partners, though its capital base is understood to include institutional allocators and family offices seeking targeted biotech exposure. Spyre's single-PM model distinguishes it from the multi-manager platform funds that have come to dominate biotech investing.
What investment stages does Spyre Therapeutics target?
Spyre invests in publicly traded biotechnology and specialty pharmaceutical companies, typically those in mid-to-late-stage clinical development. The firm favors companies with upcoming Phase 2 or Phase 3 trial readouts and regulatory catalysts within an 18-to-36-month window. Spyre generally avoids preclinical-stage risk and large-cap pharma, where clinical events are less binary.
Does Spyre Therapeutics take an activist role in its portfolio companies?
Yes. Perkins regularly engages with company boards and management teams on clinical trial design, capital allocation, and strategic alternatives. Unlike passive biotech investors, Spyre uses its concentrated positions to push for operational changes, including trial-enrollment acceleration and earlier regulatory engagement with the FDA.
What is Spyre Therapeutics' track record and performance disclosure policy?
Spyre does not publicly disclose its returns or performance metrics. As a private investment adviser, it is not required to report quarterly holdings or performance to the public. Perkins' individual track record at Fidelity—where she managed the Fidelity Select Biotechnology Portfolio—provides the primary public window into her investment style, with that fund outperforming its benchmark during her tenure (per Morningstar, 2015).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: